1 enrolling by invitation, 1 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Enrolling by invitation 1, Terminated 1 |
| Phase 2 | 1 | Enrolling by invitation 1 |
Follow Epithelial Cancer Patients: new trials by email Literature Review of Epithelial Cancer Patients trials Research Report on Epithelial Cancer Patients
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I/IIa Clinical Trial of IMC001 in Patients With Advanced Epithelial Solid Tumors. Autologous CAR-T cell injection targeting EpCAM - Epithelial Cancer Patients | Phase 1 / Phase 2 | Enrolling by invitation | Suzhou Immunofoco Biotechnology Co., Ltd | 30 | 2026-03-05 | 2026-06-12 |
| A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients catumaxomab - Epithelial Cancer Patients | Phase 1 | Terminated | Neovii Biotech | 16 | 2011-02-01 | 2013-07-02 |
Neoplasms by Histologic Type (1) · Neoplasms, Glandular and Epithelial (1)
catumaxomab (1)
Neovii Biotech (1) · Suzhou Immunofoco Biotechnology Co., Ltd (1)
Austria (1) · China (1) · Denmark (1) · Spain (1)
Christian Dittrich, Prim.Univ.-Prof. (1) · Josep Tabernero, MD (1) · Morten Sorenesen, MD, Ph.D. (1)